ReviewImmunoTargets and therapy2022
The Meat of the Matter: Understanding and Managing Alpha-Gal Syndrome.
Review in ImmunoTargets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens.The Journal of clinical investigation · 2026Article
- Unusual Causes of Food-Induced Anaphylaxis - A Review.Indian dermatology online journal · 2026Article
- Alpha-gal xenoantigens in bioprosthetic valve recipients: clinical implications for bioprosthesis longevity.Journal of cardiothoracic surgery · 2026Review
- Alpha-gal-specific human IgE promotes both alpha-gal-induced and antigen-independent allergic effector cell activation.The Journal of allergy and clinical immunology · 2026Article
- Beefing Up Awareness: Navigating Alpha-Gal Syndrome.Clinical journal of oncology nursing · 2026Review
- Article
- Allergic reactions associated with tsetse fly bites.Annals of medicine · 2025Article
- Ticked Off: Allergic Effector Cells in the Pathogenesis of Alpha-gal Syndrome.Current allergy and asthma reports · 2025Review
- Advances in Food Processing Techniques for Allergenicity Reduction and Allergen Identification.Foods (Basel, Switzerland) · 2025Review
- Alpha-Gal Syndrome in the Heartland: Dietary Restrictions, Public Awareness, and Systemic Barriers in Rural Kansas.Nutrients · 2025Article
- Alpha-Gal Syndrome-A Series of Cases with Different Clinical Pictures.International journal of molecular sciences · 2025Article
- Pre-clinical strategies and emerging technologies driving advances in the alpha-gal syndrome.Allergology international : official journal of the Japanese Society of Allergology · 2025Review
- IgG to Galactose-Alpha-1,3-Galactose: Impact of Alpha-Gal IgE Sensitization, Blood Type, and Tick Bites.Antibodies (Basel, Switzerland) · 2025Article
- Is Zebrafish a Good Model for the Alpha-Gal Syndrome?FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Safety of MMR vaccination evaluated in children with food and gelatin allergy in Iran.BMC pediatrics · 2025Article
- Alpha-gal syndrome in general practice: red meat food allergy caused by UK ticks.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Article
- Alpha-Gal Syndrome: Often Hidden, Under-Recognized, and in Need of Attention-A Rapid Review.International journal of general medicine · 2025Review
- Genetically modified pigs with α1,3-galactosyltransferase knockout and beyond: a comprehensive review of xenotransplantation strategies.Frontiers in immunology · 2025Review
- Alpha-Gal Syndrome in a Military Member.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Alpha-gal syndrome is an unconventional food allergy, characterized by IgE-mediated hypersensitivity responses to the glycan galactose-alpha-1,3-galactose (alpha-gal) and not to a food-protein. In this review, we discuss how alpha-gal syndrome reframes our current conception of the mechanisms of pathogenesis of food allergy. The development of alpha-gal IgE is associated with tick bites though the possibility of other parasites promoting sensitization to alpha-gal remains. We review the immune cell populations involved in the sensitization and effector phases of alpha-gal syndrome and describe the current understanding of why allergic responses to ingested alpha-gal can be delayed by several hours. We review the foundation of management in alpha-gal syndrome, namely avoidance, but also discuss the use of antihistamines, mast cell stabilizers, and the emerging role of complementary and alternative therapies, biological products, and oral immunotherapy in the management of this condition. Alpha-gal syndrome influences the safety and tolerability of medications and medical devices containing or derived from mammalian products and impacts quality of life well beyond food choices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.